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ACE inhibitors, 
propranolol, 
and statins 
reduce mortality 
in patients 
with diastolic 
heart failure.
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EVIDENCE-BASED ANSWER
A
 Which medications benefi t 
patients with diastolic heart 
failure?
 angiotensin-converting enzyme
  inhibitors (ACEIs), proprano-
lol, statins, furosemide, and some an-
giotensin receptor blockers (ARBs) benefi t 
patients. Medications that reduce mortal-
ity in diastolic heart failure include ACEIs 
(strength of recommendation [SOR]: C, 
1 prospective cohort trial with matched 
controls), propranolol (SOR: B, 1 random-
ized controlled trial [RCT]), and statins 
(SOR: C, 1 prospective cohort trial). 
Furosemide improves symptoms of 
heart failure and quality of life (SOR: C, 
1 RCT, using cohort data). 
ARBs show mixed results: cande-
sartan decreases hospital admissions 
(SOR: B, 1 large RCT); losartan improves 
exercise duration and quality of life 
(SOR: B, 2 small RCTs); irbesartan doesn’t 
improve heart failure symptoms or other 
outcomes (SOR: B, 1 large RCT). 
Evidence summary
Diastolic heart failure, defi ned as classic evi-
dence of congestive heart failure with “pre-
served” or “normal” left ventricular ejection 
fraction (LVEF),1 is often encountered in 
medical practice. Unfortunately, studies that 
address diastolic heart failure don’t use a 
uniform ejection fraction to defi ne preserved 
systolic function. Treatments for diastolic 
failure have included diuretics, ACEIs, ARBs, 
beta-blockers, calcium channel blockers, di-
goxin, and statins. 
ACEIs decrease mortality
One small prospective study in France en-
rolled 358 subjects who were admitted for 
a fi rst episode of heart failure but had ejec-
tion fractions ≥50%. Patients were separated 
into 2 groups based on whether or not they 
were prescribed an ACEI—lisinopril (32.3%), 
ramipril (25.6%), perindopril (23.8%), or 
enalapril (5.5%)—at discharge. Th e authors 
attempted to adjust for selection bias by de-
veloping a propensity score and comparing 
matched controls.
Patients who had been prescribed ACEIs 
had a 10% reduction in 5-year mortality 
(number needed to treat [NNT]=10).2 
ARBs produce mixed outcomes
Evidence regarding outcomes with ARBs is 
not clear cut. Candesartan was studied in 
the CHARM-Preserved Trial, which enrolled 
3023 patients from 618 centers in 26 countries 
with New York Heart Association functional 
class II to class IV congestive heart failure of 
at least 4 weeks’ duration and LVEF >40%.3 
Th e treatment group showed a signifi cant de-
crease in hospital admission for congestive 
heart failure (NNT=30, covariate adjusted), 
but no improvement in mortality. 
Losartan improved exercise duration 
and quality of life compared with placebo or 
hydrochlorothiazide in 2 small RCTs totaling 
60 patients.4,5 
In the I-PRESERVE Trial, irbesartan 
didn’t improve primary or secondary out-
comes, including death from any cause or 
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Diuretics alone 
improved 
patients’ 
quality of life.
hospitalization for a cardiovascular cause 
(P=.35), death or hospitalization from heart 
failure, or quality of life (P=.44).6 However, 
concomitant use of other medications could 
have been a factor because 39%, 28%, and 
73% of patients in the irbesartan group and 
40%, 29%, and 73% in the placebo group were 
taking an ACEI, spironolactone, or a beta-
blocker, respectively.
Propranolol reduces mortality, but data 
on other beta-blockers are lacking 
One prospective randomized trial of heart 
failure patients with LVEF ≥40% already treat-
ed with an ACEI and a diuretic, found that 
propranolol reduced total mortality by 35% 
after 1 year of therapy (absolute risk reduc-
tion=20%; NNT=5).7 Studies of other beta-
blockers haven’t reported patient-oriented 
outcomes as an end point.
Diuretics alone outperform 
diuretics plus other meds
A study that randomized 150 elderly patients 
with symptomatic heart failure and LVEF 
>45% to diuretics alone (80% were given furo-
semide), diuretics plus irbesartan, or diuret-
ics plus ramipril found that diuretics alone 
improved the quality of life score by 46% af-
ter 52 weeks and also improved symptoms of 
heart failure.8 No signifi cant symptomatic or 
other benefi t was noted with the addition of 
irbesartan or ramipril.
Statins are linked to lower mortality
A prospective cohort study followed 137 pa-
tients with heart failure and ejection fraction 
>50% for a mean of 21 months.9 After ad-
justment for diff erences in baseline clinical 
variables between groups, therapy with vari-
ous statins (68% of patients were on atorv-
astatin) was associated with lower mortality 
(NNT=5). 
Little evidence exists to support the use 
of calcium channel blockers, digoxin, or other 
vasodilators in diastolic heart failure.
Recommendations
Th e TABLE summarizes recommendations of 
the American College of Cardiology Founda-
tion and the American Heart Association.1 JFP
TABLE
Treating the patient with heart failure and normal LVEF: 
Recommendations from the ACCF and AHA
Recommendation Level of evidence
Control systolic and diastolic hypertension Good supportive evidence
Control ventricular rate in patients with atrial fi brillation Expert opinion/limited evidence
Use diuretics for pulmonary congestion and peripheral 
edema
Expert opinion/limited evidence
Perform coronary revascularization if ischemia is having 
an adverse effect
Expert opinion/limited evidence
Rhythm control in patients with atrial fi brillation may be 
useful
Expert opinion/limited evidence
Beta-adrenergic blocking agents, ACEIs, angiotensin II
receptor blockers, or calcium antagonists may be 
effective 
Expert opinion/limited evidence
Digitalis isn’t clearly effective Expert opinion/limited evidence
ACCF, American College of Cardiology Foundation; ACEIs, angiotensin-converting enzyme inhibitors; AHA, American Heart 
Association; LVEF, left ventricular ejection fraction. 
Adapted from: Hunt SA et al. J Am Coll Cardiol. 2009.1
CONTINUED ON PAGE 108
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